Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans

Molecular Psychiatry

Volumn 18, Issue 11, 2013, Pages 1199-1204

  Driesen, N R ^a   McCarthy, G ^b   Bhagwagar, Z ^a,c   Bloch, M ^a   Calhoun, V ^a,d   D'Souza, D C ^a   Gueorguieva, R ^b   He, G ^b   Ramachandran, R ^a   Suckow, R F ^e   Anticevic, A ^a   Morgan, P T ^a   Krystal, J H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c Bristol Myers Squib   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Functional connectivity; Gamma aminobutyric acid; Ketamine; N methyl D aspartate; Psychosis; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; KETAMINE;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CEREBELLUM VERMIS; COGNITION; CORPUS STRIATUM; FEMALE; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; HUMAN; HUMAN EXPERIMENT; INSULA; LINGUAL GYRUS; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; ORBITAL CORTEX; OSCILLATION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PULVINAR; SYMPTOM; THALAMUS VENTRAL NUCLEUS;

ADULT; BRAIN MAPPING; CEREBRAL CORTEX; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; KETAMINE; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 84888303661     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.194     Document Type: Article

References (63)

1. Krystal J, Abi-Dargham A, Laruelle M, Moghaddam B. Pharmacologic model psychoses. In: Charney D, Nestler E, Bunney B (eds) Neurobiology of Mental Illness. Oxford University Press: New York, pp 214-224, 1999
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214
3. Domino E, ChodoffF P, Corsenn G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965; 6: 279-291
4. Cohen B, Rosenbaum G, Luby E, Gottlieb J. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: Simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl), lysergic acid diethylamide (lsd-25), and amobarbital (amytal) sodium; ii. symbolic and sequential thinking. Arch Gen Psychiatry 1962; 6: 395-401
5. Rosenbaum G, Cohen B, Luby E, Gottlieb J, Yelen D. Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, lsd-25, and amobarbital (amytal) sodium; i. attention, motor function, and proprioception. Arch Gen Psychiatry 1959; 1: 651-656
6. Krystal JH, Perry Jr. EB, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62: 985-994
7. Volenweider F. Advances and pathophysiological model of hallucinogenic drug action in humans: A preamble to schizophrenia research. Pharmacopsychiatry 1998; 31(Supplement): 92-103
8. Stone J, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan R et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: A [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) 2008; 197: 401-408
9. Holcomb H, Lahti A, Medoff D, Cullen T, Tamminga C. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005; 30: 2275-2282
10. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001; 25: 165-172
11. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869-872
12. Vollenweider F, Leenders K, Scharfetter C, Antonini A, Maguire P, Missimer J et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7: 9-24
13. Breier A, Malhotra A, Pinals D, Weisenfeld N, Pickar D. Association of ketamineinduced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805-811
14. Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Mol Psychiatry 2012; 17: 664-665
15. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-2043
16. Maccaferri G, Dingledine R. Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci 2002; 22: 5462-5472
17. Jackson ME, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concommitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Neuroscience 2004; 101: 8467-8472
18. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. The Journal of Neuroscience 2007; 27: 11496-11500
19. Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H. Involvement of g-Aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 1998; 341: 45-56
20. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of Neuroscience 1997; 17: 2921-2927
21. Amitai N, Kuczenski R, Behrens MM, Markou A. Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology 2012; 62: 1422-1431
22. Castner SA, Arriza JL, Roberts JC, Mrzljak L, Christian EP, Williams GV. Reversal of ketamine-induced working memory impairments by the GABAA[alpha]2/3 Agonist TPA023. Biol Psychiatry 2010; 67: 998-1001
23. Homayoun H, Jackson M, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 2005; 93: 1989-2001
24. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-1352
25. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179: 303-309
26. Pinault D. N-Methyl d-Aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant [gamma] oscillations in the rat neocortex. Biol Psychiatry 2008; 63: 730-735
27. Wood J, Kim Y, Moghaddam B. Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs. The Journal of Neuroscience 2012; 32: 3022-3031
28. Lovett-Barron M, Turi GF, Kaifosh P, Lee PH, Bolze F, Sun X-H et al. Regulation of neuronal input transformations by tunable dendritic inhibition. Nat Neurosci 2012; 15: 423-430
29. Royer S, Zemelman B, Losonczy A, Kim J, Chance F, Magee J et al. Control of timing, rate and bursts of hippocampal place cells by dendritic and somatic inhibition. Nat Neurosci 2012; 15: 769-775
30. Cole MW, Pathak S, Schneider W. Identifying the brain's most globally connected regions. NeuroImage 2010; 49: 3132-3148
31. Cole MW, Yarkoni T, Repovš G, Anticevic A, Braver TS. Global connectivity of prefrontal cortex predicts cognitive control and intelligence. The Journal of Neuroscience 2012; 32: 8988-8999
32. Cole MW, Anticevic A, Repovs G, Barch D. Variable global dysconnectivity and individual differences in schizophrenia. Biol Psychiatry 2011; 70: 43-50
33. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Non-Patient Edition. Biometrics Research, New York State Psychiatric Institute: New York, 2002
34. Eckblad MJ, Chapman LJ, Chapman JP, Mishlove M. The revised social anhedonia scale. unpublished
35. Chapman LJ, Chapman JP, Raulin ML. Body image aberration in schizophrenia. J Abnorm Psychol 1978; 87: 399-407
36. Eckblad ML, Chapman LJ, Chapman JP. Magical ideation as an indicator of schizotypy. J Consult Clin Psychol 1983; 51: 215-222
37. Janca A, Bucholz K, Janca I. Family History Assessment Module Version 5. Washington University School of Medicine: St Louis, 1997
38. Kaye S, Opler L, Fiszbein A. Positive and Negative Syndrome Scale. Multi-Health Systems, Inc.: Toronto, Ontario, 1986
39. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi Dargham A, Morrissey K et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) 1998; 135: 213-229
40. Cox RW. AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996; 29: 162-173
41. Smith S. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143-155
42. Jenkinson M, Bannister P, Brandy M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17: 825-841
43. Woolrich M, Ripley B, Brady M, Smith S. Temporal autocorrelation in univariate linear modeling of FMRI data. NeuroImage 2001; 14: 1370-1386
44. Bell M, Lysaker P, Beam-Goulet J, Milstein R, Lindemayer J. Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiat Res 1994; 52: 295-303
45. Bryson G, Bell M, Greig T, Kaplan E. Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 1999; 38: 27-35
46. Peralta V, Cuesta MJ. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiat Res 1994; 53: 31-40
47. Lindenmayer JP, Bernstein Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J Nerv Ment Dis 1994; 182: 631-638
48. Dollfus S, Petit M, Lesieur P, Mendard JF. Principal-component analysis of PANSS and SANS-SAPS global ratings in schizophrenia patients. Eur Psychiatry 1991; 6: 251-259
49. Hakami T, Jones N, Tolmacheva E, Gaudias J, Chaumont J, Salzberg M et al. NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PLoS ONE 2009; 4: E6755-e6755
50. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH Contreras D et al. N-methyl-d-Aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 2009; 158: 705-712
51. Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH. Toward a neurobiology of delusions. Prog Neurobiol 2010; 92: 345-369
52. Yoon JH, Rokem AS, Silver MA, Minzenberg MJ, Ursu S, Ragland JD et al. Diminished orientation-specific surround suppression of visual processing in schizophrenia. Schizophr Bull 2009; 35: 1078-1084
53. Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci 1997; 61: 75-94
54. Hoffman RE, Hampson M. Functional connectivity studies of patients with auditory verbal hallucinations. Frontiers in Human Neuroscience 2012; 6: 6
55. Hoffman RE, Hampson M, Wu K, Anderson AW, Gore JC, Buchanan RJ et al. Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation. Cerebral Cortex 2007; 17: 2733-2743
56. Haber SN, Calzavara R. The cortico-basal ganglia integrative network: The role of the thalamus. Brain Res Bull 2009; 78: 69-74
57. Calzavara R, Mailly P, Haber S. Relationship between the corticostriatal terminals from areas 9 and 46, and those from area 8A, dorsal and rostral premotor cortex and area 24c: An anatomical substrate for cognition to action. Eur J Neurosci 2007; 26: 2005-2024
58. Haber S. The primate basal ganglia: Parallel and integrative networks. J Chem Neuroanat 2003; 26: 317-330
59. Oye N, Hustvelt O, Moberg ER, Pausen O, Skoglund LS. The chiral forms of ketamine as probed for NMDA receptor function in humans. In: Kameyama T, Nabeshima T, Domino E (eds) NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior vol.: 381-389NPP Books: Ann Arbor: MI, 1991
60. Smith DJ, Westfall DP, Adams JD. Ketamine interacts with opiate receptors as an agonist. Anesthesiology 1980; 53: S5
61. Cohen ML, Chan SL, Bhargava HN, Trevor AJ. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 1974; 23: 1647-1652
62. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999; 145: 193-204
63. Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y et al. Potentiation of low dose ketamine effects by naltrexone: Potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology 2006; 31: 1793-1800